Michael J. Fox Foundation

July 12, 2018

Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies

Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.

By VUMC News and Communications
November 11, 2013

Amish aid study of Parkinson genetics

Amish populations are valuable for genetic research because of their isolation, shared ancestry and homogeneous lifestyles.

By Leigh MacMillan
September 21, 2012

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

By Bill Snyder
March 11, 2011

Neuroscience drug discovery center opens at Vanderbilt

Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson’s disease, schizophrenia and other disorders of the brain.

By Bill Snyder